Indian-origin scientist leads A*STAR team growing micro-tumour models for more targeted cancer therapy

In a remarkable breakthrough, Singaporean researchers have successfully grown micro-tumour models outside the human body and used them to identify alternative treatment options for cancer patients who are suffering from resistant or metastatic disease, meaning that they fail to respond to standard-of-care cancer drugs. This innovation will offer hope to the numerous cancer patients grappling with this dreaded disease.
The study has been led by Indian-origin Dr Ramanuj Dasgupta, who is the Group Leader, Cancer Therapeutics and Stratified Oncology at the Genome Institute of Singapore (GIS) of Agency for Science, Technology and Research (A*STAR). The study has also been published in Nature Communications magazine.
Singaporean researchers have successfully grown micro-tumour models outside the human body and used them to identify alternative treatment options for cancer patients
Singaporean researchers have successfully grown micro-tumour models outside the human body and used them to identify alternative treatment options for cancer patients. Photo courtesy: health.com

This new discovery offers potential to predict treatment response to drugs and help clinicians identify appropriate therapeutic options for cancer patients.
In the study, researchers grew the patients’ own tumour material ex vivo in a dish as ‘micro-tumour avatars’, with the team successfully generating 24 patient-derived avatar-models. These micro-tumour models were then screened for therapeutic and genetic vulnerabilities against a panel of clinically relevant drugs, including standard-of-care treatments such as chemotherapy, radiotherapy or targeted anti-cancer drugs. This approach is known as phenotype-based treatment.
In addition, genomic characterisation of these models helped identify new biomarkers that could predict tumour progression as well as the patients’ response to different classes of drugs.
Personalised screening for drug sensitivity in patient-derived models. Green cells represent the primary tumour cells while the red cells represent metastatic tumours. The different micrographs represent the effect of drug treatment on primary versus metastatic tumour models derived from the same patient.
Green cells represent the primary tumour cells while the red cells represent metastatic tumours. The different micrographs represent the effect of drug treatment on primary versus metastatic tumour models derived from the same patient. Photo courtesy: GIS


Among the group of patients involved in the study, two of them went on to receive the phenotype-based treatment in the clinic, and responded remarkably well to the treatment options that were identified, including one where the tumour volume shrank by more than 95 per cent within six weeks of treatment, and the other where the expression of a cancer antigen marker in the blood was reduced by over 90 per cent.
Giving details about the study, Dr Ramanuj Dasgupta, said, “Our approach is unique in the sense that we are using phenotype-driven approaches prospectively to define real-time clinical management of disease, and then investigating the genomic basis for response to identify novel prognostic biomarkers. The ultimate goal would be for this innovative strategy to be available to every cancer patient in future.”
He added, “To truly assess what treatments may or may not work for a given patient, we need to let the patient’s own cancer cells tell us the genetic basis for their response or lack thereof to certain treatments, instead of using historically existing cell lines. This approach would be exceptionally useful where there is a lack of treatment options, for instance in late-stage patients, or a lack of clear biomarker-driven treatment strategies.”
Detailing about the efforts put in for this novel discovery, Dr Gopal Iyer, co-lead author of the study and Senior Consultant Surgical Oncologist at the NCCS ( National Cancer Centre, Singapore), said, “To get this right takes a lot more than just the work reflected in this paper alone. There were years of struggles on both sides to get protocols in place to be able to recruit patients, grow the tumours outside of the patient’s body, testing for genetic and therapeutic vulnerabilities at the screening setup at GIS. and have it run like clockwork, with data analysis in a meaningful manner, making sense of the results, bringing that information back to the hospital for discussions, and finally treating the patient again.
Cancer remains a major cause for disease-related mortality worldwide. It accounted for 8.8 million deaths in 2015; nearly 1 in 6 global deaths was due to cancer. 70 per cent of all cancer deaths afflict people in the developing world, including countries in Africa, Asia, Central and South America.
Source:http://www.connectedtoindia.com/indian-origin-scientist-leads-astar-team-growing-micro-tumour-models-for-more-targeted-cancer-2680.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more